Medicare CLFS Under PAMA: What IVD & Diagnostic Developers Must Know in 2026
Comprehensive 2026 guide to Medicare CLFS lab payment under PAMA: applicable lab rules, 3-year CDLT cycle, ADLT status, gapfilling, and CAA 2026 Section 6226 updates.
Direct Answer: How Medicare CLFS & PAMA Impact IVD Reimbursement in 2026
Medicare pays for clinical laboratory tests under the Clinical Laboratory Fee Schedule (CLFS). The Protecting Access to Medicare Act of 2014 (PAMA, Section 216(a), codifying Section 1834A of the Social Security Act) transformed the CLFS from a historical, cost-based benchmark into a market-based payment system. Under PAMA, "applicable laboratories" are required to report private payor payment rates and associated volumes for clinical diagnostic laboratory tests (CDLTs). Centers for Medicare & Medicaid Services (CMS) then uses the weighted median of these private payor rates to recalculate national Medicare payment rates.
Key 2026 regulatory and legislative updates shape this process for IVD and diagnostic test developers:
- 2026 Legislative Benchmark: Section 6226 of the Consolidated Appropriations Act, 2026 (CAA 2026), enacted on February 3, 2026, updated the data-reporting timeline for CDLTs and delayed the phase-in of CLFS payment reductions.
- Current Data-Reporting Window: The reporting window for the current 3-year CDLT cycle runs from May 1 to July 31, 2026, reflecting data collected from January 1 through June 30, 2025.
- Effective Rate Date: Payment rates calculated from the 2026 reporting cycle will take effect on January 1, 2027.
- Applicable Laboratory Threshold: A laboratory must report private payor data only if it holds a CLIA certificate, derives more than 50% of its combined Medicare revenues from the CLFS and Physician Fee Schedule (PFS), and received at least $12,500 in Medicare CLFS revenues during the 6-month collection period.
- ADLT Pathway: Novel single-laboratory tests cleared or approved by the FDA, or multi-biomarker algorithmic assays (MAAAs), can qualify as Advanced Diagnostic Laboratory Tests (ADLTs), establishing a separate initial-period pricing mechanism and an annual reporting cycle.
For IVD manufacturers, diagnostic startups, and commercial reference laboratories, understanding the CLFS framework is essential for US commercialization. While test developers themselves are rarely reporting entities unless they operate a CLIA-certified reference lab, PAMA rate-setting directly determines the top-line Medicare revenue ceiling for their test kits and assays across all clinical sites.
How PAMA Turned the CLFS Into a Market-Based Fee Schedule (Section 216(a) and SSA Section 1834A)
Prior to 2018, Medicare reimbursed outpatient clinical laboratory tests using local fee schedules established by Medicare Administrative Contractors (MACs) and capped by a National Limitation Amount (NLA). These rates were established under the Deficit Reduction Act of 1984 and largely relied on historical charge data adjusted for inflation. Over 30 years, this structure led to Medicare payment rates that significantly exceeded prices negotiated by commercial managed-care plans and private payors.
Congress enacted Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) to tie Medicare laboratory reimbursement directly to commercial market rates. PAMA added Section 1834A to the Social Security Act (SSA), mandating that Medicare payment rates for CDLTs equal the weighted median of private payor rates reported by applicable laboratories.
Under the historical system, Medicare laboratory payment operated under a rigid, uncoordinated patchwork of contractor-specific price ceilings. Each local Medicare Administrative Contractor maintained its own fee schedule, resulting in significant regional payment disparities for identical laboratory tests performed in different states. Furthermore, because these legacy fee schedules received only minor consumer price index adjustments over time, Medicare payment failed to reflect technological advancements, automation-driven cost reductions, or aggressive commercial rate discounting negotiated by private health plans.
PAMA fundamentally restructured this landscape by substituting administrative rate-setting with market-driven transparency. Under Section 1834A, CMS establishes a single, uniform national payment rate for every covered clinical diagnostic laboratory test code. The statutory mandate requires applicable laboratories to report private payor data—defined as the actual final allowed amount paid by commercial health plans, Medicare Advantage plans, and Medicaid Managed Care organizations—along with the total volume of tests paid at each rate. By aggregating this data across the entire commercial marketplace, CMS establishes a new fee schedule reflecting real-world market clearing prices.
CMS promulgated the final implementing regulations for Section 1834A on June 23, 2016 (81 FR 41386, codified at 42 CFR Part 414, Subpart G). The first market-based rate reset took effect on January 1, 2018. Under the statutory formula, if private payors pay less on average than Medicare, the CLFS payment rate drops. To prevent sudden market disruption, PAMA originally capped annual rate reductions at 10% per year for 2018–2020 and 15% per year for subsequent years.
For broader background on how IVD devices are classified and regulated prior to reimbursement, see our comprehensive guide to IVD device regulation and classification.
Are You an Applicable Laboratory? The Three-Part Test and the $12,500 Threshold
Not every facility that performs laboratory testing is required—or permitted—to report data to CMS under PAMA. CMS limits data reporting to "applicable laboratories" to minimize administrative burden on low-volume providers while attempting to capture representative commercial pricing.
Under 42 CFR § 414.502, an entity qualifies as an applicable laboratory if it satisfies a strict three-part statutory test during the designated 6-month data-collection period:
1. The CLIA Certificate Requirement
The entity must be certified under Section 353 of the Public Health Service Act (the Clinical Laboratory Improvement Amendments, or CLIA), or be an entity that bills for clinical laboratory tests under a CLIA certificate (such as an independent clinical laboratory or a physician office laboratory). This requirement ensures that only licensed, operational diagnostic entities capable of billing Medicare directly are included in the reporting pool.
2. The Majority Revenue Test
The entity must derive more than 50% of its total Medicare revenues (Part A and Part B) from the CLFS and/or the Physician Fee Schedule (PFS) during the collection period. This requirement historically excluded hospital laboratory testing. Because hospital laboratories derive the vast majority of their Medicare revenue from inpatient prospective payment systems (IPPS) and outpatient prospective payment systems (OPPS), hospital-based labs initially failed the majority revenue test.
To address widespread complaints from independent laboratories that early PAMA data was heavily skewed toward discounted high-volume commercial reference labs, CMS amended the regulations. Effective January 1, 2019, CMS permits a hospital outreach laboratory—defined as a hospital-based lab that bills for laboratory services furnished to non-hospital patients using the 14x Type of Bill (TOB)—to evaluate the majority revenue test based solely on the revenue billed under its own National Provider Identifier (NPI) or 14x TOB revenue, rather than total hospital facility revenue.
3. The Low-Volume Threshold
An entity that meets the majority revenue test is exempt from reporting if it received less than $12,500 in Medicare Part B CLFS payments during the 6-month data-collection period. For physician office laboratories (POLs) that bill under a group practice Tax Identification Number (TIN), the $12,500 threshold applies at the TIN level.
+-----------------------------------------------------------------------------------+
| APPLICABLE LABORATORY EVALUATION MATRIX |
+-----------------------------------------------------------------------------------+
| Entity Type | Primary Revenue Source | Typically Applicable Lab? |
+-----------------------+------------------------+----------------------------------+
| Independent Lab | CLFS / Commercial | YES (if CLFS revenue >= $12,500) |
| Physician Office Lab | PFS / CLFS | YES (if TIN meets revenue test) |
| Hospital Inpatient Lab| IPPS (Part A) | NO (fails majority revenue test) |
| Hospital Outreach Lab | 14x TOB (Part B) | YES (if 14x TOB revenue test met)|
| IVD Test Manufacturer | Device Sales / Reagents| NO (does not bill Medicare CLFS) |
+-----------------------------------------------------------------------------------+
Understanding the applicable laboratory designation is crucial for commercial structuring. IVD manufacturers that partner with commercial reference laboratories must recognize that their lab partners bear the legal and operational burden of reporting private payor rates to CMS. If a manufacturer offers volume discounts, reagent rental agreements, or bundled equipment pricing to a reference lab, those commercial terms may indirectly influence the net allowed amounts that the laboratory negotiates with private payors, ultimately impacting the PAMA rate reported to CMS during the next collection cycle.
The 3-Year CDLT Reporting Cycle vs. the Separate ADLT Cycle
PAMA establishes two distinct tracks for diagnostic laboratory tests based on whether a test is classified as a Clinical Diagnostic Laboratory Test (CDLT) or an Advanced Diagnostic Laboratory Test (ADLT).
What Data Must Applicable Laboratories Report?
During an active reporting window, each applicable laboratory must submit the following specific data elements to CMS for every CDLT performed during the collection period:
- HCPCS Code: The specific Healthcare Common Procedure Coding System code assigned to the test.
- Private Payor Rate: The actual final paid rate negotiated with each private payor. This reflects the allowed amount after applying contractual adjustments, excluding patient cost-sharing (deductible and coinsurance) and uncollected balances.
- Total Volume: The total number of test volume units paid by each private payor at each specific rate.
The definition of a private payor under PAMA is broad, encompassing commercial health insurers, health maintenance organizations (HMOs), preferred provider organizations (PPOs), Medicare Advantage plans under Medicare Part C, and Medicaid Managed Care organizations. However, payments received directly from traditional fee-for-service Medicare Part A or Part B, traditional state Medicaid fee-for-service programs, or direct out-of-pocket patient self-pay amounts are explicitly excluded from data reporting.
+-----------------------------------------------------------------------------------+
| CDLT VS. ADLT REGULATORY COMPARISON |
+-----------------------------------------------------------------------------------+
| Parameter | CDLT Track | ADLT Track |
+------------------------+----------------------------------+-----------------------+
| Statutory Definition | Standard diagnostic lab test | Novel single-lab test |
| | offered by multiple laboratories | (FDA cleared/approved |
| | or standard methodology | or complex algorithm) |
| Reporting Frequency | Every 3 years | Annually |
| Data Collection Window | 6-month period (Jan 1 - Jun 30) | 6-month annual period |
| Initial Rate Setting | Crosswalking or Gapfilling | Actual List Charge |
| | by local MACs | for first 3 quarters |
| Applicable Entities | All applicable labs | Single laboratory |
| | performing the test | developing/owning test|
| Rate Floor/Cap | Max 15% annual reduction cap | No initial cap after |
| | (per CAA 2026 phase-in) | weighted median calculated
+-----------------------------------------------------------------------------------+
For details on how HCPCS codes intersect with broader medical device procedural coding, consult our guide to CPT, HCPCS and ICD coding strategy for devices.
What Section 6226 of CAA 2026 Changed in 2026 and What It Means for 2027 Rates
Congress has repeatedly intervened to delay PAMA reporting periods and payment reductions to protect laboratory infrastructure during public health crises and economic shifts. The most recent legislative adjustment occurred on February 3, 2026, when Congress passed Section 6226 of the Consolidated Appropriations Act, 2026 (CAA 2026).
The statutory adjustments enacted under Section 6226 reflect ongoing congressional concern over the potential destabilization of the domestic clinical laboratory sector. Prior to the passage of CAA 2026, clinical laboratories faced imminent, multi-year rate reductions of up to 15% across hundreds of high-volume diagnostic tests. Industry stakeholders, led by the American Clinical Laboratory Association (ACLA) and the College of American Pathologists (CAP), presented evidence to lawmakers demonstrating that cumulative PAMA cuts, combined with post-pandemic inflationary pressures on labor, reagents, and cold-chain logistics, threatened patient access to routine diagnostic testing, particularly in rural and underserved communities.
+-----------------------------------------------------------------------------------+
| CHRONOLOGY OF PAMA RATE ACTION |
+-----------------------------------------------------------------------------------+
| Period / Legislation | Action Taken |
+-------------------------------+---------------------------------------------------+
| 2018-2020 (original PAMA) | First market-based reset; cuts capped at 10%/yr, |
| | based on 2016 private-payer data reported in 2017 |
| CARES Act (2020) | First congressional pause: suspended the next |
| | reporting cycle and held cuts at 0% for 2021 |
| Successive appropriations | Between 2021 and 2026 Congress delayed the |
| measures (2021-2025) | reporting cycle roughly six times in all, holding |
| | CLFS reductions at 0% each year |
| CAA 2026 Section 6226 (2026) | Restored reporting (May 1-Jul 31, 2026) using |
| | 2025 data; resumes cuts at up to 15%/yr in 2027 |
+-----------------------------------------------------------------------------------+
Key Requirements of Section 6226 (CAA 2026):
- Reporting Window: Applicable laboratories must submit private payor data between May 1, 2026, and July 31, 2026.
- Data Collection Scope: Data reported during this window reflects private payor payments collected from January 1, 2025, through June 30, 2025.
- Payment Reduction Phase-In: For calendar year 2026, payment rates for CDLTs cannot be reduced below 2025 levels (0% reduction cap). For calendar years 2027 through 2029, payment reductions resulting from the 2026 data reporting are capped at 15% per year.
- Effective Implementation Date: The new market-based rates derived from the 2026 reporting window take effect on January 1, 2027.
+-----------------------------------------------------------------------------------+
| 2026-2027 PAMA IMPLEMENTATION TIMELINE |
+-----------------------------------------------------------------------------------+
| Date Range | Operational Milestone |
+-------------------------------+---------------------------------------------------+
| Jan 1, 2025 - Jun 30, 2025 | Data Collection Period (6 months of payor rates) |
| Feb 3, 2026 | Enactment of CAA 2026 Section 6226 |
| May 1, 2026 - Jul 31, 2026 | Active Data Reporting Window for Applicable Labs |
| Aug 1, 2026 - Nov 2026 | CMS Data Aggregation & Weighted Median Calculation|
| Nov 2026 | Publication of Proposed 2027 CLFS Rate File |
| Jan 1, 2027 | New Market-Based CLFS Rates Take Effect Nationwide|
+-----------------------------------------------------------------------------------+
How a Test's Rate Is Actually Set: Weighted-Median Rates, Gapfilling, and the NLA
Once data reporting closes, CMS calculates the new CLFS rate for each test code using a precise mathematical formula established under SSA Section 1834A.
1. The Weighted Median Formula
The payment rate for a HCPCS code is calculated as the volume-weighted median of all private payor rates reported for that test.
Mathematically, CMS sorts all reported private payor rates for a given HCPCS code in ascending order, along with their associated test volumes. The volume-weighted median is the private payor rate at which 50% of the total reported test volume falls at or below that rate, and 50% falls at or above it. This calculation ensures that high-volume national commercial contracts exert a proportionally greater influence on the resulting national Medicare rate than low-volume regional contracts.
+-----------------------------------------------------------------------------------+
| EXAMPLE WEIGHTED MEDIAN CALCULATION |
+-----------------------------------------------------------------------------------+
| Lab Entity | Reported Payor Rate ($) | Paid Test Volume | Total Extended Value |
+---------------+-------------------------+------------------+----------------------+
| Lab A | $45.00 | 10,000 | $450,000 |
| Lab B | $50.00 | 25,000 | $1,250,000 |
| Lab C | $65.00 | 15,000 | $975,000 |
| Lab D | $80.00 | 8,000 | $640,000 |
+---------------+-------------------------+------------------+----------------------+
| TOTALS | -- | 58,000 | $3,315,000 |
+-----------------------------------------------------------------------------------+
| RESULT: Cumulative volume reaches 29,000 (50th percentile) at the $50.00 rate. |
| New Medicare CLFS Rate = $50.00 |
+-----------------------------------------------------------------------------------+
2. Pricing New Tests: Crosswalking vs. Gapfilling
When a manufacturer launches a novel IVD or diagnostic assay that receives a new CPT or HCPCS code, no historical private payor data exists in CMS records. CMS uses two administrative mechanisms under 42 CFR § 414.508 to establish the initial fee schedule rate:
- Crosswalking: Applied when a new test is syntactically or methodologically similar to an existing test already listed on the CLFS. CMS assigns the new test the exact payment rate of the existing code (or a multiple of that code). Crosswalking is common for incremental line extensions, automated immunoassay modifications, or updated panel configurations where underlying reagent and labor costs closely mirror existing diagnostic codes.
- Gapfilling: Applied when no comparable test exists on the fee schedule. CMS instructs local MACs to establish regional payment amounts for the first year based on local pricing factors, including:
- Charges for the test and routine discounts
- Resources required to perform the test (equipment, reagents, personnel, overhead)
- Payment amounts assigned by other payors (commercial health plans, Medicaid)
- Costs associated with reagent test kits and automated equipment
The gapfilling process represents a critical commercial milestone for diagnostic developers. During the initial gapfill year, local MAC contractors examine cost dossiers, clinical utility data, and early commercial invoices submitted by laboratories performing the test. Each contractor establishes a local regional rate. At the conclusion of the gapfill year, CMS collects all contractor-established rates and calculates the median rate, which becomes the National Limitation Amount (NLA) for the code. This NLA serves as the national CLFS payment rate until the test is formally captured in a subsequent 3-year PAMA reporting cycle.
For broader device reimbursement context, review our medical device reimbursement overview.
ADLT vs. CDLT: How a Single-Laboratory IVD Can Escape the 3-Year Cut Cycle
For diagnostic developers bringing proprietary, high-complexity tests to market, obtaining Advanced Diagnostic Laboratory Test (ADLT) status under SSA Section 1834A(d) provides a strategic regulatory advantage.
What Qualifies as an ADLT?
Under 42 CFR § 414.502, an ADLT is a clinical diagnostic laboratory test covered under Medicare Part B that is furnished by a single laboratory and meets one of the following criteria:
- Criterion 1 (FDA Clearance or Approval): The test is an in vitro diagnostic test cleared or approved by the FDA under Section 510(k), De Novo classification, or Premarket Approval (PMA). Note that to satisfy Criterion 1, the test must be performed solely by the single laboratory that holds the FDA clearance or approval (or an entity under common ownership).
- Criterion 2 (Multi-Biomarker Algorithmic Assay): The test is an in vitro diagnostic test that is an analysis of multiple biomarkers of DNA, RNA, or proteins, combined with a unique algorithm to yield a single patient-specific result (such as a risk score or probability index), and is performed solely by the single laboratory that developed the test.
The Commercial Advantage of ADLT Status
- Initial List Charge Pricing: For the first three calendar quarters of market availability, Medicare pays the test's Actual List Charge (the publicly listed charge billed to non-Medicare payors). This provision allows innovative diagnostic developers to establish a fair commercial valuation without suffering immediate MAC gapfill discounting.
- Clawback Risk Management: If the actual list charge exceeds the weighted median calculated after the initial period by more than 13%, the laboratory must refund the difference to CMS. However, if managed correctly, this provides predictability during early commercial rollout.
- Annual Reporting: ADLT rates are recalculated annually based on private payor data, insulating the test from the 3-year CDLT pricing ratchets.
+-----------------------------------------------------------------------------------+
| ADLT STATUS STRATEGIC TRADE-OFFS |
+-----------------------------------------------------------------------------------+
| Benefits | Strategic & Operational Costs |
+----------------------------------------+------------------------------------------+
| Reimbursed at List Charge in Q1-Q3 | Must maintain exclusive single-lab model |
| Annual rate updates reflect price rises| Clawback penalty if List Charge > 13% |
| Bypasses standard MAC gapfill delays | High data submission burden every year |
| Stronger valuation for diagnostic IP | Cannot license kit to third-party labs |
+-----------------------------------------------------------------------------------+
Diagnostic developers must carefully evaluate the strategic trade-off between the single-laboratory ADLT business model and a broad decentralized kit-distribution model. While ADLT status protects initial payment rates and allows annual rate updates, it restricts commercial distribution to a centralized CLIA laboratory model. If a manufacturer intends to sell IVD test kits to thousands of independent, hospital, and physician office laboratories worldwide, it cannot maintain ADLT status. Once decentralized distribution begins, the test transitions into the standard CDLT category, subjecting its fee schedule rate to the 3-year market-based private payor ratchet.
MAC Local Coverage Determinations (LCDs) and the MolDX Program
Securing a CLFS payment rate under PAMA establishes how much Medicare pays for a laboratory test, but it does not guarantee that Medicare will pay for the test. Coverage—the determination of whether a test is medically necessary for a specific patient indication—is governed separately through National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) issued by Medicare Administrative Contractors.
For molecular diagnostic testing, genomic panels, and next-generation sequencing (NGS) assays, coverage is primarily managed through the Molecular Diagnostic Services (MolDX) Program. Originally established by Palmetto GBA, the MolDX program has been adopted by multiple MAC jurisdictions, including Noridian, CGS, and WPS, covering a majority of US states.
+-----------------------------------------------------------------------------------+
| MOLDX REGISTRATION AND COVERAGE STEPS |
+-----------------------------------------------------------------------------------+
| Phase | Required Operational Action |
+-----------------------+-----------------------------------------------------------+
| Z-Code Application | Register test details in the DEX Diagnostics Exchange to |
| | obtain a unique, test-specific Z-Code identifier. |
| Clinical Dossier | Submit analytical validity, clinical validity, and |
| Submission | clinical utility evidence to the MolDX review team. |
| Technical Assessment | Undergo rigorous review of assay precision, sensitivity, |
| (TA) Review | specificity, and actionable clinical decision utility. |
| LCD Publication | Receive favorable Local Coverage Determination (LCD) or |
| | coverage article specifying covered ICD-10 diagnoses. |
+-----------------------------------------------------------------------------------+
The interaction between MolDX Z-Codes and PAMA pricing is a critical consideration for molecular diagnostic companies. Even if a lab obtains a standard CPT code and reports private payor rates under PAMA, MACs operating under the MolDX program will reject claims if the laboratory fails to bill with a valid, active Z-Code linked to a favorable coverage determination. Therefore, diagnostic developers must align their PAMA reimbursement strategy with a concurrent MolDX technical assessment strategy.
Data Reporting Compliance, Civil Monetary Penalties, and Audits
Data reporting under PAMA is a mandatory statutory obligation for applicable laboratories, enforced through severe administrative penalties under SSA Section 1834A(a)(9).
Congress established strict enforcement provisions to ensure that applicable laboratories submit complete, accurate, and truthful private payor data. If an applicable laboratory fails to report required private payor data during an active reporting window, or if it submits false, misleading, or incomplete data, the Secretary of Health and Human Services is authorized to impose Civil Monetary Penalties (CMPs) of up to $10,000 per day for each failure to report and for each item of false or fraudulent information submitted.
+-----------------------------------------------------------------------------------+
| PAMA COMPLIANCE AND AUDIT RISK FRAMEWORK |
+-----------------------------------------------------------------------------------+
| Risk Category | Operational Trigger | Statutory Penalty |
+-----------------------+---------------------------------------+-------------------+
| Failure to Report | Applicable lab ignores reporting | Up to $10,000/day |
| | window (May 1 - Jul 31, 2026) | per violation |
| Inaccurate Rates | Reporting gross charges instead of | CMPs + False |
| | net contractually allowed amounts | Claims Act risk |
| Omitted Payor Volume | Excluding low-rate commercial plans | Administrative |
| | to artificially inflate median rate | audit & CMPs |
| Misclassified Entity | Misapplying majority revenue test | Mandatory back-log|
| | to evade reporting obligations | reporting + CMPs |
+-----------------------------------------------------------------------------------+
To maintain compliance, laboratories must establish robust internal auditing controls. Finance and billing departments must maintain auditable record trails linking every reported private payor rate to verified electronic remittance advices (ERAs), Explanation of Benefits (EOB) statements, and signed commercial payor contracts. These records must be retained for a minimum of 6 years following submission to withstand OIG and CMS administrative audits.
PAMA Cut History, the $3.8 Billion Estimate, and the SALSA/RESULTS Reform Landscape
The financial impact of PAMA on the US clinical laboratory industry has been substantial. According to data compiled by the American Clinical Laboratory Association (ACLA), successive rounds of PAMA rate reductions cut total Medicare CLFS funding by an estimated $3.8 billion between 2018 and 2025.
Industry Structure Impact
Because large independent reference laboratories (such as Quest Diagnostics and Labcorp) negotiate high-volume discounts with commercial health plans, the weighted median rates reported under PAMA dropped sharply for routine automated chemistry, hematology, and immunoassay panels. Roughly 800 high-volume laboratory tests faced statutory maximum cuts of 10% per year from 2018 to 2020.
+-----------------------------------------------------------------------------------+
| CLFS PAYMENT CUT IMPACT BY TEST CATEGORY |
+-----------------------------------------------------------------------------------+
| Test Category | Representative CPT Codes | Average Cumulative Cut |
+---------------------------+--------------------------+----------------------------+
| Basic Metabolic Panel | 80048 | -30.0% (max statutory cut) |
| Comprehensive Metabolic | 80053 | -30.0% (max statutory cut) |
| Lipid Panel | 80061 | -30.0% (max statutory cut) |
| Complete Blood Count (CBC)| 85025 | -28.5% |
| Hemoglobin A1c | 83036 | -30.0% (max statutory cut) |
| Thyroid Stimulating Horm. | 84443 | -27.2% |
+-----------------------------------------------------------------------------------+
The Legislative Reform Landscape (SALSA and RESULTS Acts)
To replace temporary legislative delays with permanent structural reform, laboratory trade associations and medical societies have advocated for two key bipartisan bills in Congress:
- Saving Access to Laboratory Services Act (SALSA): SALSA represents the primary legislative reform proposal backed by ACLA, CAP, and over 50 medical organizations. SALSA would replace the current full-population reporting burden with a statistically valid random sampling methodology for independent, hospital outreach, and physician office laboratories. Furthermore, SALSA would establish permanent guardrails on annual rate adjustments, capping maximum annual payment reductions at 5% per year while allowing upward rate adjustments when market data demonstrates increasing private payor prices.
- RESULTS Act Proposal: A complementary legislative framework focused on capping annual fee schedule reductions at 5% per year while eliminating statutory caps on upward rate adjustments, ensuring that Medicare reimbursement dynamically tracks inflationary increases in commercial healthcare costs.
For diagnostic developers evaluating point-of-care testing (POCT) and decentralization strategies, fee schedule stability is critical. See our analysis of point-of-care testing regulation and CLIA.
Step-by-Step Action Plan for Diagnostic & IVD Test Developers
To protect commercial reimbursement under the CLFS framework, diagnostic test developers should execute a structured five-step market access strategy:
- Determine Coverage & Billing Track (CDLT vs. ADLT): Evaluate whether your novel diagnostic assay should be commercialized as a centralized single-laboratory test seeking ADLT status or as a broad IVD reagent kit sold to third-party reference labs.
- Secure Coding & Crosswalk/Gapfill Strategy: Apply for dedicated CPT or HCPCS codes during the AMA CPT Editorial Panel cycles. Prepare comprehensive cost and resource dossiers for MAC gapfilling during the first year of code listing.
- Monitor Applicable Laboratory Status: If operating a commercial CLIA laboratory, perform semi-annual calculations of the majority revenue test and low-volume threshold ($12,500) per 42 CFR § 414.502.
- Build Commercial Data-Collection Infrastructure: Implement automated financial accounting systems capable of isolating net final paid private payor rates from commercial contracts, excluding copays, deductibles, and secondary payor adjustments.
- Prepare for the Active Reporting Window: Ensure verified private payor data collected between January 1, 2025, and June 30, 2025, is formatted and submitted to CMS between May 1 and July 31, 2026, to establish accurate CLFS payment rates for January 1, 2027.
If your IVD or diagnostic system is utilized in hospital inpatient or outpatient surgical settings rather than independent labs, evaluate add-on payment mechanisms such as new technology add-on payment and OPPS pass-through for devices.
Frequently Asked Questions (FAQs)
Does a hospital outreach laboratory have to report under PAMA?
Yes, if it meets the applicable laboratory criteria. Under CMS regulations effective since 2019, if a hospital outreach laboratory bills for laboratory services furnished to non-hospital patients under its own NPI or using the 14x Type of Bill (TOB), and derives more than 50% of its Medicare revenues from the CLFS/PFS while meeting the $12,500 threshold during the collection period, it must report private payor data.
If my IVD test is cleared by the FDA but offered by many labs, is it an ADLT or a CDLT?
It is a CDLT. To qualify as an ADLT under Criterion 1 or Criterion 2, the test must be furnished solely by a single laboratory that developed or owns the assay. Once an IVD manufacturer sells reagent test kits broadly to multiple independent or hospital laboratories, the test loses single-laboratory exclusivity and is priced under the standard 3-year CDLT cycle.
When do the next CLFS payment cuts take effect and how large can they be?
Under Section 6226 of the Consolidated Appropriations Act, 2026 (CAA 2026), payment cuts are capped at 0% for calendar year 2026. Payment cuts resulting from the May 1 – July 31, 2026 data reporting window will take effect on January 1, 2027, and are capped at a maximum reduction of 15% per year for 2027, 2028, and 2029.
How does PAMA/CLFS interact with FDA LDT policy for laboratory-developed tests?
PAMA governs Medicare payment and pricing, whereas FDA regulations govern premarket safety and oversight. A laboratory-developed test (LDT) performed in a single CLIA lab can seek ADLT status under Criterion 2 (multi-biomarker algorithmic assay) without FDA clearance, provided it meets the complex algorithm and single-lab rules. However, if an LDT seeks ADLT status under Criterion 1, it must obtain formal FDA clearance or approval.
What counts as a final paid private-payer rate for reporting purposes?
A final paid rate is the actual net amount paid by a commercial health plan for a specific test, including contractual allowances. It excludes patient deductible, coinsurance, secondary payor payments, disputed claims, uncollected balances, and capitation payments where an individual test price cannot be isolated.
Sources & Regulatory References
- CMS PAMA Reporting Resources: CMS CLFS PAMA Reporting & Resources - Official guidance on reporting windows, applicable lab rules, and reporting systems.
- CMS CLFS Main Page: CMS Clinical Laboratory Fee Schedule Hub - Base fee schedule files, gapfilling policies, and annual public meeting notices.
- CMS ADLT Guidance: CMS Advanced Diagnostic Laboratory Tests Information - Criteria, application instructions, and list of approved ADLTs.
- PAMA Final Rule (81 FR 41386): Federal Register PAMA Final Rule - Authoritative regulatory text codified at 42 CFR Part 414 Subpart G.
- Protecting Access to Medicare Act of 2014: PAMA Public Law 113-93 - Statutory text establishing SSA Section 1834A.
- Consolidated Appropriations Act, 2026: Enacted February 3, 2026 (Section 6226 updates to CDLT data reporting and payment cut phase-in).
- American Clinical Laboratory Association (ACLA): ACLA PAMA Reform & Stop Lab Cuts - Industry association analysis of historical cuts and legislative reform positions (SALSA/RESULTS).